Search for: "MedImmune, Inc. v. Genentech, Inc"
Results 81 - 100
of 156
Sorted by Relevance
|
Sort by Date
5 Dec 2022, 6:55 am
Citing the Supreme Court’s ruling in MedImmune, Inc. v. [read post]
5 Dec 2022, 6:55 am
Citing the Supreme Court’s ruling in MedImmune, Inc. v. [read post]
5 Dec 2022, 6:55 am
Citing the Supreme Court’s ruling in MedImmune, Inc. v. [read post]
8 Dec 2011, 2:50 pm
Did the court of appeals err in adopting a new and inflexible rule, contrary to normal standing rules and this Court’s decision in MedImmune, Inc. v. [read post]
25 Sep 2006, 7:00 am
MedImmune v. [read post]
8 Jul 2011, 1:37 pm
Significance for Patent Owners Finding mechanisms to contact potential licensees has been problematic after MedImmune, Inc. v. [read post]
6 Apr 2014, 7:42 pm
” MedImmune, Inc. v. [read post]
31 Jul 2014, 4:30 am
See MedImmune v. [read post]
5 Oct 2015, 6:43 am
In MedImmune, Inc. v. [read post]
21 Aug 2008, 9:43 pm
Following the Federal Circuit's decision in Teva Pharmaceuticals USA, Inc. v. [read post]
21 Dec 2010, 12:00 pm
"[Plaintiff] argues that the present controversy satisfies the immediacy prong of [MedImmune, Inc. v. [read post]
21 Sep 2011, 5:44 am
Genentech, Inc., 549 U.S. 118 (2007). [read post]
12 Dec 2011, 1:37 pm
Genentech, Inc., 549 U.S. 118 (2007)….? [read post]
8 Dec 2009, 12:33 pm
The court noted that the Supreme Court’s decision in MedImmune, Inc. v. [read post]
19 Oct 2007, 4:10 am
The Court, therefore, relied upon the Supreme Court’s recent MedImmune, Inc. v. [read post]
15 Aug 2008, 10:31 pm
Genentech, Inc., 127 S. [read post]
14 Sep 2017, 1:30 pm
” Citing to MedImmune v. [read post]
29 Oct 2013, 7:42 am
The case follows directly from the Court’s 2007 reversal of the Federal Circuit in MedImmune, Inc. v. [read post]
8 Sep 2016, 11:29 am
The leading precedent actual-controversy precedent for patent cases is the Supreme Court’s 2007 decision in MedImmune, Inc. v. [read post]
11 Mar 2015, 9:40 am
MercExchange, L.L.C., 547 U.S. 388 (2006) (injunctive relief) MedImmune, Inc. v. [read post]
